What are the common side effects of Elacetrant? What should patients pay attention to when taking it?

Elacestrant (Elacestrant) is an oral selective estrogen receptor degrader (SERD), mainly used to treat breast cancer Adenocarcinoma is especially for patients with advanced or metastatic breast cancer that is estrogen receptor positive (ER+), HER2negative, and has developed resistance after previous endocrine therapy. As a new type of endocrine therapy drug, elastran is generally well tolerated in clinical use, but there is still a certain risk of side effects. Patients need to focus on possible adverse reactions and preventive measures during use. This article will provide a detailed analysis from four aspects: common side effects, serious adverse reactions, monitoring during medication and patient precautions.

First of all, the common side effects of elastran are mainly concentrated in the gastrointestinal tract and systemic reactions. Patients may experience nausea, vomiting, diarrhea, constipation, loss of appetite and other symptoms while taking the medication. Most of these reactions are mild to moderate and can generally be alleviated by adjusting the diet or taking the medication in divided doses. In addition, some patients may experience fatigue, weakness, headache, or mild muscle and joint pain. These symptoms are usually more obvious in the early stages of taking the drug and may be relieved as the body gradually adapts to the drug. Clinical data show that approximately 20% to 30% of patients may experience these mild to moderate side effects, so early identification and intervention are important.

Secondly, we need to pay attention to the serious adverse reactions that elastrast may cause. Although rare, some patients may experience abnormal liver function, prolonged QT interval, or thrombotic events while taking the drug. Abnormal liver function is manifested by elevated serum ALT and AST, which in severe cases can cause jaundice or liver failure; prolongation of the QT interval may lead to arrhythmia or even sudden cardiac death, so patients with cardiovascular disease need to be particularly cautious. Patients with previous blood clots or coagulation abnormalities also need to be closely monitored and should seek medical attention immediately if symptoms such as chest pain, difficulty breathing, or swelling of the lower limbs occur.

Again, monitoring and management during medication are crucial. It is recommended that patients undergo basic hematology, liver function and electrocardiogram tests before taking elastran, and then review them regularly according to the doctor's recommendations. For patients with mild gastrointestinal symptoms, intervention can be performed by adjusting the medication time, taking it with food, or supplementing it with antiemetic and antidiarrheal drugs. For patients with hematological or liver function abnormalities, the dose should be adjusted or the drug temporarily discontinued based on the test results. In addition, patients should maintain a healthy lifestyle, including a reasonable diet, moderate exercise and adequate sleep, to enhance physical fitness and reduce the incidence of side effects.

Finally, patients should also pay attention to interactions with other drugs while taking elastran. Elastran is mainly metabolized by the liverCYP3A4 and is therefore closely related to CYP3A4The combined use of inhibitors or inducers may affect drug blood concentrations, increase side effects or reduce efficacy. Patients should truthfully provide their doctors with a list of all medications they are taking, including Chinese herbal medicines and health supplements. At the same time, follow your doctor's guidance and avoid increasing or decreasing the dose or stopping the medication on your own. For female patients, menstrual changes and bone density should be closely monitored throughout the treatment cycle to facilitate timely intervention.

In summary, although elastran, as a new ER inhibitor, has shown significant efficacy in the treatment of advanced breast cancer, patients still need to pay attention to gastrointestinal reactions, fatigue, liver function and cardiovascular risks during use. Through early identification of side effects, regular monitoring of indicators, reasonable life intervention and adjustment of medication regimens in accordance with doctor's instructions, treatment safety and efficacy can be ensured to the greatest extent. Patients should maintain close communication with their doctors and promptly report any abnormal symptoms to achieve personalized and precise treatment, prolong survival and improve quality of life.

Reference materials:https://www.drugs.com/